Clinical Trial Update: STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of ganetespib (STA-9090) for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• STA-9090 (ganetespib) (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: AML, CML | Phase 1 | Status: COMPLETED